Health Care & Life Sciences » Pharmaceuticals | Chong Kun Dang Pharmaceutical Corp.

Chong Kun Dang Pharmaceutical Corp. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
517,909
544,130
592,493
831,986
884,363
956,219
Cost of Goods Sold (COGS) incl. D&A
56,954
267,137
299,716
499,734
526,863
578,005
Gross Income
460,955
276,993
292,777
332,252
357,499
378,214
SG&A Expense
123,454
220,194
246,099
267,370
275,869
302,392
EBIT
45,319
54,097
42,863
61,335
77,847
75,822
Unusual Expense
-
1,080
2,133
2,078
-
842
Non Operating Income/Expense
3,933
2,270
21,889
1,904
299
4,513
Interest Expense
5,704
5,367
4,353
4,171
3,510
2,712
Pretax Income
36,044
48,482
15,138
56,788
74,599
68,340
Income Tax
9,543
13,328
21,910
15,842
20,871
26,636
Consolidated Net Income
26,502
35,154
6,773
40,946
53,728
41,704
Net Income
26,502
35,154
6,773
40,946
53,807
42,399
Net Income After Extraordinaries
26,502
35,154
6,773
40,946
53,807
42,399
Net Income Available to Common
26,502
35,154
6,773
40,946
53,807
42,399
EPS (Basic)
2,685.71
3,560.00
685.71
4,146.66
5,449.52
4,313.39
Basic Shares Outstanding
10
10
10
10
10
10
EPS (Diluted)
2,683.06
3,560.26
685.92
4,146.90
5,449.43
4,313.39
Diluted Shares Outstanding
10
10
10
10
10
10
EBITDA
64,917
74,478
65,382
85,183
99,750
96,958
Other Operating Expense
292,181
2,702
3,815
3,547
3,784
-
Non-Operating Interest Income
362
942
650
144
609
585
Minority Interest Expense
-
-
-
-
79
694
Equity in Affiliates (Pretax)
-
-
-
346
647
-

About Chong Kun Dang Pharmaceutical

View Profile
Address
8 Chungjeong-ro
Seoul SL 03742
Korea, Republic Of
Employees -
Website http://www.ckdpharm.com
Updated 07/08/2019
Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetic, antivirus, beta-blocking, anti-hyperlipidemia and others. The company was founded on November 2, 2013 and is headquartered in Seoul, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.